Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
395 hedge funds and large institutions have $13.6B invested in Intra-Cellular Therapies Inc. in 2025 Q1 according to their latest regulatory filings, with 159 funds opening new positions, 88 increasing their positions, 118 reducing their positions, and 149 closing their positions.
247% more funds holding in top 10
Funds holding in top 10: 15 → 52 (+37)
68% more capital invested
Capital invested by funds: $8.08B → $13.6B (+$5.52B)
29% more call options, than puts
Call options by funds: $367M | Put options by funds: $284M
2% more funds holding
Funds holding: 387 → 395 (+8)
7% more first-time investments, than exits
New positions opened: 159 | Existing positions closed: 149
25% less repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 118
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$647M |
| 2 |
HI
HBK Investments
Dallas,
Texas
|
+$546M |
| 3 |
DKCM
Davidson Kempner Capital Management
New York
|
+$434M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$383M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$381M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.05B |
| 2 |
JP Morgan Chase
New York
|
-$544M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$373M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$302M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$271M |
ITCI Hedge Fund Activity: Q1 2025 in Review
395 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2025, worth a combined $13.6B — up 68% from $8.08B a quarter earlier.
Buyers outnumbered sellers: 159 funds opened new ITCI positions and 149 closed out — a net gain of 10 holders — while 88 added to existing stakes and 118 trimmed.
The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $647M. The largest seller was Fidelity Investments, cutting an estimated $1.05B.
- 395 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2025, up from 387 in Q4 2024.
- Funds reported $13.6B of Intra-Cellular Therapies Inc. stock for Q1 2025, up 68% quarter-over-quarter.
- 159 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2025 and 149 closed out, a net change of +10 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q1 2025 was Pentwater Capital Management, an estimated $647M added.
- The largest Intra-Cellular Therapies Inc. seller in Q1 2025 was Fidelity Investments, an estimated $1.05B sold.
Based on aggregated 13F filings for Q1 2025.